Target intelligence / Profile preview

Immunoglobulin kappa constant (IGKC)

Target
IGKC
Molecular classification
Other (Immunoglobulin constant region, immunoglobulin superfamily)
01

Overview

Immunoglobulin kappa constant is the constant domain of the kappa-type light chain of human antibodies, encoded by the IGKC gene. It forms part of the immunoglobulin molecule produced by B lymphocytes and does not participate in antigen binding directly, but stabilizes the antibody structure and supports antibody function in the immune response. The constant region is identical in all kappa light chains and is crucial for the effector functions of secreted antibodies in humoral immunity, such as antigen clearance and immune complex formation. Measurement of kappa light chains is clinically important as a marker for conditions like multiple myeloma and other B cell malignancies, but the IGKC itself does not serve as a direct therapeutic target

Other names
Immunoglobulin kappa constantIGKCHCAK1Ig kappa chain C regionIg kappa chain C region AGIg kappa chain C region CUMIg kappa chain C region EUIg kappa chain C region OUIg kappa chain C region ROYIg kappa chain C region TIIGKCDKmimmunoglobulin kappa (invariant region)immunoglobulin kappa constant regionimmunoglobulin kappa light chain (VJ)immunoglobulin κ light chainκ light chainIG κ constant
02

Mechanism of action

Not applicable (the constant region is not a direct target for drug action; mechanisms generally involve antigen binding by antibodies)

03

Biological functions

Immune responseantigen bindinghumoral immunityadaptive immune response
04

Disease associations

CancerImmunodeficiencyInfection (indirectly, as a component of antibodies)Other
05

Safety considerations

None specific; abnormal levels or clonality (overproduction) are a marker of disease, not a direct drug safety consideration
06

Interacting drugs

None (the IGKC is not a direct drug target; drugs may bind immunoglobulins as a class, but not the IGKC region specifically)
07

Biomarkers

Immunoglobulin kappa light chain (κ chain) can be used as a biomarker for:- Monoclonal gammopathies, e.g., multiple myeloma (κ/λ ratio)- B cell clonality assessment in lymphoproliferative disorders

Beyond the preview

Go deeper on Immunoglobulin kappa constant (IGKC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin kappa constant (IGKC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call